Innate Pharma Unveils Pipeline Progress and Strategic Focus on Cancer Antibody Therapies
I'm PortAI, I can summarize articles.
Innate Pharma SA has unveiled its strategic priorities and clinical pipeline, focusing on high-value assets like IPH4502, lacutamab, and monalizumab. The pipeline targets high unmet medical needs, including various cancers and autoimmune diseases. Lacutamab is advancing towards potential accelerated approval and Phase 3 initiation. The company highlights its antibody engineering expertise and global partnerships, with over €3 billion in potential milestone payments. The presentation details collaborations and agreements in Europe.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments